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OBJECTIVEdWe studied whether patterns of glucose absorption during oral glucose toler-
ance tests (OGTTs) were abnormal in individuals with impaired glucose regulation and whether
they were related to sex and body size (height and fat-free mass). We also examined how well
differences in insulin sensitivity and b-cell function measured by gold-standard tests were reﬂected
in the corresponding OGTT-derived estimates.
RESEARCH DESIGN AND METHODSdWith validated methods, various aspects of
glucose absorption were estimated from 12-point, 3-h, 75-g OGTTs in 66 individuals with
normal glucose tolerance (NGT), isolated impaired fasting glucose (i-IFG), or isolated impaired
glucose tolerance (i-IGT). Insulin sensitivity and b-cell function were measured with the euglycemic-
hyperinsulinemic clamp and intravenous glucose tolerance tests, respectively. Surrogate markers
of both conditions were calculated from OGTTs.
RESULTSdMore rapid glucose absorption (P # 0.036) and reduced late glucose absorption
(P # 0.039) were observed in the i-IFG group relative to NGT and i-IGT groups. Women with
i-IGT had a lower early glucose absorption than did men with i-IGT (P = 0.041); however, this
difference did not persist when differences in body size were taken into account (P . 0.28).
Faster glucose absorption was related to higher fasting (P = 0.001) and lower 2-h (P = 0.001)
glucose levels and to greater height and fat-free mass (P, 0.001). All OGTT-derivedmeasures of
insulin sensitivity, but only one of three measures of b-cell function, reﬂected the differences for
these parameters between those with normal and impaired glucose regulation as measured by
gold-standard tests.
CONCLUSIONSdGlucose absorption patterns during an OGTT are signiﬁcantly related to
plasma glucose levels and body size, which should be taken into account when estimating b-cell
function from OGTTs in epidemiological studies.
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Individuals with the prediabetic condi-tions of impaired fasting glycemia(IFG) and impaired glucose tolerance
(IGT) have a higher risk of developing
type 2 diabetes than do individuals with
normal glucose tolerance (NGT) (1,2).
Several studies have shown that men in
general have higher fasting plasma glu-
cose (FPG) levels and a higher prevalence
of isolated IFG (i-IFG) than do women
(3–6). In contrast, women often exhibit
higher glucose levels after a standard
75-g oral glucose tolerance test (OGTT)
and consequently have a higher preva-
lence of isolated IGT (i-IGT) (3,4,6)
than do men. We and others have previ-
ously suggested that the difference in
post-OGTT glucose concentration is a
consequence of the relatively higher
dose of glucose given to women com-
pared with men when seen in relation to
their body size (3,4,7). Speciﬁcally, it has
been shown that there are no sex differ-
ences in post-OGTT 2-h plasma glucose
(2hPG) levels after adjustment for body
height (3,4,7). It has also been suggested,
however, that the higher 2hPG levels in
women may be attributed to differences
in glucose absorption patterns between
men and women (8). Healthy women
with NGT seem to have lower glucose ab-
sorption from the gut during the ﬁrst
hour of an OGTT than do their male
counterparts, whereas glucose absorption
is higher in women than in men during
the last hour of a 3-h OGTT (8). Whether
such sex differences in glucose absorption
patterns can be explained by differences
in body size has not been previously
determined.
Several factors inﬂuence blood glu-
cose concentrations after a meal or an
OGTT. In addition to gastric emptying
and small intestine digestion and absorp-
tion, peripheral insulin sensitivity and the
amount of insulin secreted in response to
glucose and incretin hormones are major
determinants of postprandial or post-
OGTT glucose concentration (9–11).
The relative contributions of these various
factors remains uncertain and controver-
sial (10). More than 20 years ago it was
shown that the amount of glucose absorbed
in response to varying glucose loads is
diminished in individuals with type 2 di-
abetes (12). Furthermore, a recent study
showed that pregnant women with gesta-
tional diabetes mellitus had markedly
lower glucose absorption than pregnant
women with NGT (13). The mechanisms
underlying these associations are not well
understood. Moreover, it is unclear
whether defects in glucose absorption
are already present in individuals with
slightly elevated blood glucose levels,
those with IFG or IGT.
Through the use of OGTTs, many
methods for estimating b-cell function
and insulin sensitivity have been suggested
(14–16). These estimates reﬂect discrete
aspects of b-cell function (ﬁrst phase,
second phase, static, dynamic) and
more or less speciﬁc sites of insulin sen-
sitivity (liver, periphery, whole body),
but none of them take into account po-
tential differences in glucose absorption
patterns among the tested persons. In this
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study, we examined whether patterns of
glucose absorption during OGTTs dif-
fered between individuals with normal
and impaired glucose regulation and
whether they were related to sex and
body size. In addition, we examined how
well the differences in insulin sensitivity
and b-cell function between normal and
impaired glucose regulation as estimated
by gold-standard tests were reﬂected





A subset of study participants of white
ethnicity were recruited from the Danish
nonpharmacological intervention study
Inter99. The Inter99 study aimed to
examine the effect of a nonpharmaco-
logical intervention on the development
of diabetes and cardiovascular morbid-
ity and mortality (17). A total of 6,784
participants were examined with a stan-
dard 75-g OGTT at baseline (1999–
2001). After 5 years of follow-up, all
participants were invited to a clinical ex-
amination, including an OGTT, to de-
termine glucose tolerance status. We
subsequently invited a subset of 66 in-
dividuals who had progressed from
NGT (FPG ,6.1 and 2hPG ,7.8
mmol/L) to i-IFG (n = 18, FPG $6.1
and 2hPG ,7.8 mmol/L) or i-IGT (n =
28, FPG ,6.1 and 2hPG $7.8 mmol/L)
during the 5 years of follow-up, as well
as a control group who had NGT both at
the baseline and at the 5-year follow-up
examination (n = 20). For each glucose
tolerance group, we aimed for equal
proportions of men and women; how-
ever, we were only able to recruit two
women with i-IFG and thus could not
study sex differences in that particular
group. A group with combined IFG and
IGT was not included, because the aim
of the study was to examine the mecha-
nisms responsible for isolated defects in
fasting and 2-h glucose metabolisms.
Further details about recruitment, clas-
siﬁcation, and study population have
been published elsewhere (18,19). All
study procedures took place at Steno
Diabetes Center A/S, Gentofte, Den-
mark, in 2005–2007. All study partici-
pants gave written informed consent to
participate, and the study was approved
by the local ethics committee and con-
ducted in accordance with the Helsinki
declaration.
Examinations
Standard 75-g OGTTs were performed
after an overnight fast. Samples were
drawn at 210, 0, 10, 20, 30, 45, 60, 75,
90, 120, 150, and 180 min for assessment
of plasma glucose and serum insulin con-
centrations. On a separate day, the 66 par-
ticipants underwent an examination of
insulin sensitivity and b-cell function by
means of the euglycemic-hyperinsulinemic
clamp technique combined with an intra-
venous glucose tolerance test (IVGTT).
After an overnight fast, blood samples
were taken and a 2-h basal tracer equili-
bration period was initiated. The 2-h
basal period was followed by a 30-min
IVGTT to characterize ﬁrst-phase insulin
secretion. After the IVGTT, a euglycemic-
hyperinsulinemic clamp at 40 mU/m2/min
for 2 h was performed for estimation of
peripheral insulin sensitivity (20). A
primed-constant [3-3H]glucose infusion
was used throughout the entire study pe-
riod, and [3-3H]glucose was added to the
glucose infusates to maintain a constant
plasma speciﬁc activity during the clamp
period.
Body weight (BW) was measured to
the nearest 0.1 kg with an electronic
standard scale (Tanita, BWB-620A) with
the participant wearing light clothes, and
height was measured to the nearest 0.5
cm with the participant not wearing
shoes. Total body fat and fat-free mass
were determined with a bioimpedance
analyzer (Biodynamics, Seattle, WA) (21).
Body surface area was calculated according
to the formula of DuBois and DuBois (22).
Gut glucose absorption
The details for the estimation of glucose
absorption have been reported elsewhere
(8). Here we summarize the description in
brief. For a given BW in the post-OGTT
state, the increase in circulating glucose
over time (dgluccirc/dt) is determined by
the gain from gut glucose absorption
and endogenous glucose production
(EGP) as well as the loss because of glu-
cose disposal (Rd). Accordingly, changes
in glucose concentration over time can be
expressed as follows: dgluccirc/dt = 1/VG3
[BW 3 (EGP 2 Rd) + ABS], with initial
conditions of gluc(0) equal to FPG. In this
equation, VG is the oral distribution vol-
ume, which in this case is only a scaling
factor assumed as 9% of BW (23). Time-
dependent rates of EGP and Rd during the
OGTT were estimated by a validated
method (8). We used this equation to cal-
culate gut glucose absorption (ABS in the
equation).
For each participant, total glucose
absorption during the OGTT was calcu-
lated by integrating glucose absorption
rates across the 180-min OGTT. Glucose
half-life (T1/2) in the gastrointestinal tract
(i.e., time until half of the total glucose
had been absorbed from the gut) was in-
dividually determined by linear curve inter-
polation of the relative glucose retention
during theOGTT by the closest time points
to cross the 50% threshold (24).
Estimates of insulin sensitivity and
b-cell function
The gold-standard estimate of peripheral
insulin sensitivity was calculated as the
mean glucose infusion rate per kg fat-
free mass during the last 30 min of the
euglycemic-hyperinsulinemic clamp
(M value). In addition to this measure,
we estimated insulin sensitivity from the
OGTT according to commonly used
surrogate markers: 1) the Matsuda index
(25), including plasma glucose and se-
rum insulin taken at 0, 30, 60, 90, and
120 min during the OGTT; 2) the insulin
sensitivity index (ISI0–120) (26), includ-
ing 0- and 120-min glucose and insulin
values as well as BW; and 3) the BIGTT-SI
index (16), which is calculated from glu-
cose and insulin concentrations measured
at 0, 30, and 120 min and also from sex
and BMI.
A reliable and widely accepted esti-
mate of ﬁrst-phase insulin response was
obtained from the IVGTT by calculating
the incremental area under the serum
insulin curve during the ﬁrst 10 min after
the glucose bolus. Surrogate markers of
ﬁrst-phase insulin secretion (b-cell func-
tion) were estimated from the OGTT by
various methods: 1) the insulinogenic in-
dex (27), modeling the change in serum
insulin divided by the change in plasma
glucose from 0 to 30 min; 2) the Stumvoll
ﬁrst-phase insulin secretion index (28),
which includes information on serum in-
sulin at 0 and 30 min as well as plasma
glucose at 30 min; and 3) the BIGTT-AIR
(16), which uses, in addition to sex and
BMI, information on plasma glucose
and serum insulin concentrations at 0, 30,
and 120 min.
Laboratory analysis
Blood samples formeasurement of venous
plasma glucose during the OGTT and
IVGTT, as well as [3-3H]glucose during
the clamp, were taken in a tube containing
sodium ﬂuoride and put on ice immedi-
ately. Plasma glucose was analyzed with
the hexokinase and glucose-6-phosphate
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dehydrogenase technique (Roche Diagnos-
tics, Mannheim, Germany). [3-3H]Glucose
activity was determined from evaporated
plasma samples (29). Plasma [3-3H]water
was determined from the activity in the
plasma sample minus the activity in the
same plasma sample after evaporation.
During the clamp, whole blood glucose
was measured on a One Touch Proﬁle
glucose meter (LifeScan, Milpitas, CA).
Measurement of serum insulin was per-
formed with the ﬂuoroimmunoassay
technique (AutoDELFIA; Perkin Elmer-
Wallac, Turku, Finland).
Statistical analysis
First, we examined whether speciﬁc di-
mensions of glucose absorption differed
among individuals of discrete glucose
tolerance status (NGT vs. i-IFG vs. i-IGT).
We calculated total glucose absorption,
early (0–60 min) and late (60–120 min)
glucose absorptions, time to peak glucose
absorption, peak glucose absorption, and
the velocity of glucose absorption (T1/2).
Next, we studied potential differences in
glucose absorption patterns between men
and women with NGT or i-IGT. Pairwise
differences in dimensions of glucose ab-
sorption as well as measures of insulin sen-
sitivity and b-cell function between groups
(glucose tolerance status, sex, or both)were
tested with t tests. We also studied associ-
ations of T1/2 with continuously measures
of FPG and 2hPG as well as with body size
(height and fat-free mass) in the entire
study population bymeans of linear regres-
sion analysis. Moreover, we examined
whether differences in body size could ex-
plain any observed differences in glucose
absorption patterns using linear regression
models. Finally, we studied whether the
OGTT-derived measures of insulin sensi-
tivity and b-cell function also reﬂected
the differences found between normal
and impaired glucose regulation measured
by the gold-standardmethods and howdif-
ferences in velocity of glucose absorption
(T1/2) affected the associations. All glucose
absorption data, ISI0–120, and all estimates
of b-cell function were logarithmically
transformed before analysis to fulﬁll the
assumption of normality of the residuals.
Statistical analyses were performed in SAS
version 9.2 (SAS Institute, Inc, Cary, NC),
and a two-sided 5% signiﬁcance level was
used.
RESULTS
Glucose absorption patterns and
glucose tolerance status
Clinical characteristics and dimensions of
glucose absorption in individuals with
NGT, i-IFG, and i-IGT are shown inTable 1.
Median glucose absorptions at 11 discrete
time points during the OGTT in individ-
uals with NGT, i-IFG, and i-IGT are
shown in Fig. 1. The T1/2 was signiﬁcantly
shorter in the i-IFG group compared with
the NGT group (P = 0.036) and the i-IGT
group (P = 0.001). Moreover, the time to
peak of glucose absorption was shorter
(P = 0.013) and late glucose absorption
(60–120 min) was lower (P = 0.011) in
participants with i-IFG than in those
with NGT. Total glucose absorption also
tended to be lower in those with i-IFG
Table 1dClinical characteristics, dimensions of glucose absorption, and estimates of insulin sensitivity and b-cell function in individuals
with NGT, i-IFG and i-IGT
NGT (n = 20) i-IFG (n = 18) i-IGT (n = 28) P value
Clinical characteristics
Men (n) 11 16a,b 16 0.039
Age (years) 49.8 (10.6) 53.9 (7.5) 14.0 (8.2) 0.19
Height (cm) 174.7 (9.6) 176.4 (8.8) 169.9 (9.0)b 0.039
BMI (kg/m2) 25.6 (3.3) 27.8 (3.6)a 27.9 (3.5)c 0.042
Waist-to-hip ratio 0.87 (0.09) 0.96 (0.07)a* 0.93 (0.08)c* 0.003
Fat-free mass (kg) 59.6 (48.5–67.1) 63.7 (55.8–76.1)a,b 55.3 (49.3–66.2) 0.032
FPG (mmol/L) 5.4 (0.4) 6.2 (0.3)a**,b** 5.7 (0.4) ,0.0001
2hPG (mmol/L) 6.6 (1.2) 5.7 (1.4) 8.5 (0.9)b**,c** ,0.0001
Glucose absorption patterns
Total glucose absorption (g) 71.6 (60.5–78.2) 60.2 (40.5–75.2) 63.7 (43.3–80.7) 0.23
Early glucose absorption, 0–60 min (g) 33.5 (30.1–43.8) 34.5 (23.9–45.2) 32.0 (22.2–40.1) 0.19
Late glucose absorption, 60–120 min (g) 27.1 (22.7–30.5) 13.7 (10.8–26.8)a,b 24.7 (15.7–30) 0.036
Peak glucose absorption (g) 0.73 (0.64–0.86) 0.86 (0.57–1.01) 0.76 (0.55–0.93) 0.42
Time to peak (min) 30 (20–45) 20 (10–30)a 30 (10–45) 0.049
T1/2 (min) 60 (55–70) 50 (40–65)
a,b* 65 (60–75) 0.007
Estimates of insulin sensitivity
M value (clamp, mg per kg fat-free mass) 8.9 (7.1–10.2) 8.0 (5.8–9.8) 6.2 (4.6–8.0)c* 0.017
Matsuda index (OGTT) 19.0 (13.2–23.2) 15.9 (10.3–20.8) 11.4 (8.7–18.8)c 0.042
ISI0–120 (OGTT) 34.4 (28.2–39.4) 44.0 (36.1–48.5) 22.4 (19.0–25.8)
b**,c** ,0.0001
BIGTT-SI (OGTT) 8.7 (6.7–6.7) 7.6 (6.2–6.2) 5.0 (3.7–3.7)b*,c* 0.004
Estimates of b-cell function
FPIR (IVGTT, nmol/L) 1.6 (0.8–3.7) 1.1 (0.7–1.5)a,b 1.8 (1.0–2.6) 0.049
Insulinogenic index30 min (OGTT) 57.8 (42.5–129.0) 67.1 (39.8–108.9) 66.5 (40.0–88.0) 0.77
Stumvoll ﬁrst-phase (OGTT) 577 (460–1,001) 634 (413–986) 729 (516–1,098) 0.49
BIGTT-AIR (3103) (OGTT) 1.6 (1.2–2.0) 1.3 (1.0–1.6)a,b* 1.7 (1.4–2.5) 0.031
Data are mean (SD) or median (IQR), or proportions (95% CI), except as marked. Level of signiﬁcance P, 0.05 except as marked. FPIR, ﬁrst-phase insulin response.
aDifference signiﬁcant for i-IFG versus NGT. bDifference signiﬁcant for i-IFG versus i-IGT. cDifference signiﬁcant for i-IGT versus NGT. *Level of signiﬁcance P ,
0.01. **Level of signiﬁcance P , 0.0001.
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than in those with NGT (P = 0.086). The
same ﬁndings were observed when only
men were analyzed (data not shown).
When FPG was analyzed as a continuous
variable, we found an inverse relationship
with T1/2 (P = 0.001; Fig. 2A).
Early glucose absorption (0–60 min)
tended to be lower in those with i-IGT than
in those with NGT (P = 0.068) (Table 1),
but other dimensions of glucose absorption
did not differ between individuals with
i-IGT and NGT. Nevertheless, higher
2hPG concentrations were signiﬁcantly
related to slower glucose absorption in
the entire study population (P = 0.001)
(Fig. 2B).
Glucose absorption patterns and
sex differences
We found no differences in any dimen-
sions of glucose absorption between men
and women with NGT (P $ 0.121 for all
comparisons). Within the i-IGT group,
early glucose absorption was slightly
lower in women with i-IGT (median
29.9 g, interquartile range [IQR] 15.1–
34.3 g) compared with men with i-IGT
(median 34.6 g, IQR 27.0–44.2 g; P =
0.041). Also, peak glucose absorption
was lower in women with i-IGT (median
0.62 g, IQR 0.36–0.79 g) than in men with
i-IGT (median 0.80 g, IQR 0.58–0.98 g; P =
0.015). In addition, T1/2 tended to be lon-
ger in women with i-IGT (median 72.5
min, IQR 65–77.5 min) than in their
male counterparts (median 65.0 min, IQR
60.0–70.0 min; P = 0.096), indicating a
slower glucose absorption. No other di-
mensions of glucose absorption differed
by sex within the i-IGT group (P $ 0.205
for all other comparisons).
Glucose absorption patterns and
body size
The velocity of glucose absorption (T1/2)
was inversely associated with both height
and the amount of fat-free mass (P ,
0.001) (Fig. 2C and D). We therefore
subsequently adjusted all analyses for
height or fat-free mass together with
age. In the adjusted analyses, late glucose
absorption was still signiﬁcantly lower in
the i-IFG group than in the NGT group
(P , 0.01), and T1/2 and time to peak
were signiﬁcantly shorter in the i-IFG
group than in both the i-IGT (P ,
0.05) and NGT (P , 0.05) groups. All
signiﬁcant differences between men and
women within the i-IGT group disap-
peared after adjustment for age and
height or fat-free mass (P $ 0.22 for
all). The relationships of T1/2 with FPG
and 2hPG concentrations were slightly
attenuated but remained signiﬁcant after
adjustment for age and height or fat-free
mass (P , 0.022 for all).
Insulin sensitivity and b-cell
function values obtained from gold-
standard versus OGTT measures
Individuals with i-IGT had 30% reduced
peripheral insulin sensitivity compared
with the NGT group when evaluated with
the euglycemic hyperinsulinemic clamp
(P = 0.003). This difference was captured
by all the OGTT-derived measures, with
differences in insulin sensitivity between
the i-IGT group and the NGT group of
33% for the Matsuda index (P = 0.012),
41% for ISI0–120 (P, 0.001), and 43% for
BIGTT-SI (P = 0.002) (Table 1). Adjust-
ment for T1/2 did not change these ﬁnd-
ings (P # 0.001 for all).
The i-IFG group had 42% lower ﬁrst-
phase insulin response than did the NGT
group when estimated from the IVGTT
(P = 0.026). This difference was also
found with the BIGTT-AIR index derived
from the OGTT (34% lower in i-IFG vs.
NGT; P = 0.037) (Table 1). We did not,
however, ﬁnd a signiﬁcantly lower mean
b-cell function for i-IFG versus NGT
when evaluated by the insulinogenic in-
dex (13% lower; P = 0.728) or the Stum-
voll index (7% lower; P = 0.626).
Adjustment for T1/2 resulted in larger
mean differences in the insulinogenic in-
dex (22% lower in i-IFG vs. NGT) and the
Stumvoll index (16% lower in i-IFG vs.
NGT); however, the differences were still
not signiﬁcant (P $ 0.23). The BIGTT-
AIR index was 38% lower in subjects
with i-IFG than in those with NGT after
adjustment for T1/2 (P = 0.008).
CONCLUSIONSdIn this study, we
hypothesized that glucose absorption
patterns might differ between men and
women with normal and impaired glu-
cose regulation and that such differences
may affect the estimation of insulin sen-
sitivity and insulin secretion from
OGTTs. Our data showed that individu-
als with i-IFG had faster glucose absorp-
tion during the OGTT than did those with
NGT, as indicated by an earlier peak of
glucose absorption and a shorter T1/2. In
contrast, individuals with i-IGT did not
exhibit a signiﬁcantly different glucose
absorption pattern from those with
NGT. Women with i-IGT did have slower
glucose absorption than did their male
counterparts; however, this difference
was explained by differences in body
size between men and women. We also
found that estimates of insulin sensitivity
from OGTTs resembled those measured
by gold-standard techniques, although
two of three surrogate markers of b-cell
function did not capture the b-cell dys-
function observed in i-IFG when a gold-
standard method (IVGTT) was used.
Several studies have shown that the
pathophysiologic mechanisms under-
lying the prediabetic states i-IFG and
i-IGT differ widely (18,19,30,31); how-
ever, this is the ﬁrst study to show that
the glucose absorption pattern in re-
sponse to an OGTT among individuals
with i-IFG is different from that among
those with NGT and i-IGT. The faster glu-
cose absorption rate in addition to the
normal peripheral insulin sensitivity ob-
served in those with i-IFGmay contribute
to their ability to obtain normal 2hPG
concentrations. Despite the faster glucose
absorption in the i-IFG group, early glu-
cose absorption (0–60 min) did not differ
between the groups. The reason may be
that the i-IFG group had an earlier peak
followed by a steeper decline of glucose
absorption toward 60 min relative to the
other groups (Fig. 1), resulting in similar
total glucose absorption rates in the three
groups during the ﬁrst hour. In support of
the faster glucose absorption in the i-IFG
group, we found that the velocity of glu-
cose absorption was related to the FPG
concentration. This information is impor-
tant when the OGTT is used for diagnosis
of diabetes, because faster early glucose
absorption may result in lower 2hPG lev-
els. Abnormal glucose absorption patterns
during OGTT in patients with type 2
diabetes and gestational diabetes melli-
tus (12,13) may therefore partly explain
the lack of overlap in the diagnosis of
Figure 1dGlucose absorptions during the 12-
point, 3-hOGTT in individualswithNGT (black
lines, n = 20), i-IFG (light gray lines, n = 18),
and i-IGT (dark gray lines, n = 28). Solid lines
represent medians; dashed lines are IQRs.
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diabetes when using the OGTT versus
HbA1c criteria (32).
We found that all sex differences
within the i-IGT group disappeared after
adjustment for height, fat-free mass, or
both. An explanation for the slower and
lower early glucose absorption in women
with i-IGT is thus that women in general
receive a relatively larger glucose load
than men (because of their smaller body
size). Our ﬁnding of signiﬁcantly slower
glucose absorption (T1/2) in individuals
with short height and low fat-free mass,
as well as our previous observations (3),
support this notion. In other words, the
ability to absorb and metabolize a stan-
dard OGTT seems to differ according to
stature.
The OGTT-derived estimates of in-
sulin sensitivity reﬂected the differences
found by the glucose clamp technique
between individuals with NGT and those
with i-IGT. Although the OGTT-derived
indices of insulin sensitivity have been
developed from or validated against the
clamp (16,25,26), the ﬁnding was unex-
pected because a previous study predicted
pronounced increments of OGTT-derived
indices of insulin sensitivity (i.e., reduced
insulin resistance) if intestinal glucose ab-
sorption was simulated to be reduced by
50% (11). Together, these ﬁndings illus-
trate that conclusions derived from simu-
lation models of glucose and insulin
kinetics are not always in agreement with
real-life conditions. With respect to b-cell
function, only the BIGTT-AIR index was
useful in expressing the abnormality in
ﬁrst-phase insulin response characteristic
of those with i-IFG. This index may be
superior to the other two indices because
it is derived from a tolbutamide-modiﬁed,
Figure 2dAssociations of the velocity of glucose absorption (T1/2) with FPG (A), 2hPG (B), height (C), and fat-free mass (D) in men (3) and
women (○). Solid lines represent estimated values; dashed lines are 95% CIs.
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frequently sampled IVGTT and also in-
cludes information on sex and body size
(16). The main difference between insulin
secretion during OGTT and IVGTTd
aside from glucose absorption patternsdis
the incretin effect, which is only activated
during oral glucose ingestion. The BIGTT-
AIR index thus seems to bypass differences
in both glucose absorption and incretin
hormones, thereby expressing an index
of insulin secretion independent of orally
induced factors, even though it is based on
an OGTT. Adjustment for the velocity of
glucose absorption slightly improved the
performance of the insulinogenic index
and the Stumvoll index, although not suf-
ﬁciently. Future development of new
models for assessing b-cell function on
the basis of more physiologically relevant
tests (e.g., meal tests) seems relevant to
cover real-life aspects of pancreatic b-cell
function.
The major strength of this study was
the combination of OGTT, IVGTT, and
clamp data, enabling a direct comparison
of OGTT-derived measures with gold-
standard measurements of insulin sensi-
tivity and insulin secretion. We used the
World Health Organization criteria for
categorizing individuals into the discrete
prediabetic groups, and these criteria
have a higher cutoff point for i-IFG than
that suggested by the American Diabetes
Association. However, we did ﬁnd linear
relationships of the velocity of glucose
absorption with both FPG and 2hPG
concentrations when analyzed as contin-
uous variables, so it is unlikely that the
use of the American Diabetes Association
criteria would yield very different results,
even though the distribution of partici-
pants in the various groups would be
different. A major limitation of our study
was that glucose absorption was not
measured directly but estimated by our
validated method; however, FPG and
2hPG levels only contribute a small frac-
tion to the estimation of the various
dimensions of glucose absorption, limit-
ing the possibility of overlap with the
classiﬁcation of the prediabetic groups.
Another limitation was that glucose effec-
tiveness (glucose-mediated glucose up-
take and inhibition of EGP) was not taken
into account in the glucose absorption
model because it signiﬁcantly blurred the
shape of the absorption curve (8). At high
blood glucose concentrations during the
OGTT, glucose effectiveness would re-
duce EGP and increase peripheral Rd
slightly. In general, individuals with im-
paired glucose regulation (including
diabetes) have lower glucose effectiveness
than do those with NGT (33). Because in-
clusion of glucose effectiveness in the glu-
cose absorption model gave a deviation of
10% at most (8), however, we believe that
our conclusions would not have been
changed had we included glucose effec-
tiveness in the estimation.
Unfortunately, the relatively small
study size limited a detailed study of
potential interactions among sex, glucose
tolerance status, and glucose absorption.
The presented results therefore should be
interpreted with caution and need repli-
cation in other independent datasets.
In conclusion, we found glucose
absorption patterns to be abnormal in
prediabetic individuals with i-IFG.
The velocity of glucose absorption was
inversely associated with 2hPG levels and
positively associated with FPG levels and
body size. A tall person or one with high
FPG (i.e., i-IFG) will on average have a
faster glucose absorption during an
OGTT, and thus lower 2hPG levels,
than a shorter person or one with lower
FPG. These differences are likely to affect
the estimation of b-cell function by
OGTT, as well as the diagnosis of diabetes
and prediabetic conditions. Despite the
close linkage of glucose absorption pat-
terns, plasma glucose levels, and body
size shown in this study, more studies
are needed before information on differ-
ences in glucose absorption can be used in
the treatment of patients with diabetes.
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